WS08.03 Evaluating lung, liver and gut structure and function using MRI in 6 to 11 year olds – preliminary results from the GIFT-cystic fibrosis junior cohort

Background/objectives: In the UK elexacaftor/ivacaftor/tezacaftor (ETI) is licensed for patients 6 years and over. There is a need to assess the effect of ETI on multiple organ systems. We have designed and tested an MRI protocol that is repeatable and tolerable for children aged 6 to 11 years. Our objective was to measure lung, liver and gut structure and function in cystic fibrosis (CF).